SNMMI 2024 Annual Meeting

Viewing 1-20 of 39 articles

SNMMI 2024: Response Assessment in RPTs for Prostate Cancer: Everyone’s A Winner

SNMMI 2024: Registrational Trials for PSMA PET

SNMMI 2024: Prognostic Value of Post-Therapy SPECT/CT Imaging in Patients Undergoing 177Lu-PSMA-617 Radioligand Therapy: Results from 3 Clinical Trials

SNMMI 2024: PSMA PET/CT Radiomics: Assessment of Adverse Pathological Risk and Proteomic Biomarker Correlations in Prostate Cancer

SNMMI 2024: Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu PSMA Therapy: Comparison to Quantitative SUVmean and Patient Outcomes

SNMMI 2024: 18F-DCFPyL PET/MRI Radiomics for Intraprostatic Prostate Cancer Detection and Metastases Prediction Using Whole-Gland Segmentation

SNMMI 2024: Comparison of Post-Therapy 4 and 24-hour 177Lu-PSMA SPECT/CT and Pre-Therapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castrate-Resistant Prostate Cancer

SNMMI 2024: 68Ga-P16-093 Diagnostic Performance in Newly Diagnosed Prostate Cancer- Histopathologic Correlation

SNMMI 2024: Determining the Simplified Quantification Method of [18FAlF-P16-093 for Patients with Primary Prostate Cancer

SNMMI 2024: Eligibility for PSMA-RLT Based on Dual FDG/PSMA-PET: A Subanalysis of the 3TMPO Study

SNMMI 2024: COBRA: Assessment of Safety and Efficacy of 64Cu-SAR-bisPSMA in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy

SNMMI 2024: Non-PSMA Targets for Prostate Cancer Radiopharmaceutical Therapies

SNMMI 2024: VIOLET: Radiation Absorbed Dose in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 161Tb-PSMA-I&T

SNMMI 2024: Dosimetry and Pilot Therapy Study of Novel PSMA-Targeting Agents, 177Lu-P17-087 and 177Lu-P17-088, in Metastatic Castration-Resistant Prostate Cancer Patients

SNMMI 2024: Preclinical and First-in-Human Studies of Dansylated Amino Acid Modified Long-Acting PSMA Derivative 68Ga/177Lu-LNC1011

SNMMI 2024: Combination Treatment of Prostate Cancer Using Pembrolizumab with PSMA Based Radioligands

SNMMI 2024: Safety, Tolerability, and Dosimetry of TLX591 with Best Standard of Care in Patients with PSMA-Expressing Metastatic Castration Resistant Prostate Cancer: ProstACT SELECT Preliminary Results

SNMMI 2024: PSMA PET in Patients with Prostate Cancer – Gained Insights from Eight Years of Reimbursable Imaging

SNMMI 2024: Saul Hertz’s Theranostic Dream is Shaping the Future of Cancer Care: Bridging Evidence-Based Medicine and Precision Oncology

SNMMI 2024: PSMA Radioligand Therapy in Patients with Prostate Cancer: Technical Considerations for Diagnostic, Quantitative, and Dosimetric Imaging

1
2